UFP Technologies Reports Quarterly Earnings Beat
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 25 2026
0mins
Source: NASDAQ.COM
- Earnings Beat: UFP Technologies reported quarterly earnings of $2.44 per share, surpassing the Zacks consensus estimate of $2.26, indicating stable profitability despite a slight decline from $2.46 a year ago.
- Revenue Miss: The company posted revenues of $148.92 million for the quarter, falling short of the Zacks consensus estimate of $150.5 million, although this reflects a 3.9% year-over-year increase, suggesting ongoing market demand amid challenges.
- Strong Stock Performance: UFP shares have risen approximately 8.9% since the beginning of the year, contrasting with a 0.1% decline in the S&P 500, highlighting the company's relative strength in the market and attracting investor interest.
- Cautious Outlook: With current EPS estimates at $2.55 and revenue expectations at $156.63 million, management's commentary will significantly influence short-term stock movements, prompting investors to closely monitor future earnings estimate revisions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy UFPT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on UFPT
About UFPT
UFP Technologies, Inc. is a designer and custom manufacturer of solutions for medical devices, sterile packaging, and other engineered custom products. The Company’s single-use and single-patient devices and components are used in a range of medical devices and packaging for minimally invasive surgery, infection prevention, wound care, wearables, orthopedic soft goods, and orthopedic implants. Its manufacturing operations consist primarily of cutting, routing, compression and injection molding, vacuum-forming, micro-molding, thermoforming, laminating, radio frequency and impulse welding, and assembling. It also engineers components for automotive use in interior trim and structural applications. These components are produced using a compression molding process to create functional composites consisting of various materials such as polypropylene/fiberglass panels, nonwovens, and fabrics. It also develops and manufactures precision thermo-formed and heat-sealed polymer components.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Analysis of UFP Technologies Executive Stock Transaction
- Stock Option Exercise: UFP Technologies director Cynthia L. Feldmann exercised 1,200 stock options and immediately sold them on June 12 for a total value of $287,149, indicating a need for liquidity while maintaining 5,476 shares directly, which shows continued alignment with shareholders.
- Transaction Frequency Analysis: The 1,200-share sale is larger than the previous sale of 647 shares in November 2024 but smaller than a February sale, with most trading activity related to administrative events, indicating Feldmann's low trading frequency primarily aimed at realizing option liquidity.
- Company Financial Performance: UFP Technologies reported first-quarter revenue of $154.2 million, up 4.1% year-over-year, with net income at $17.5 million, reflecting a 5.9% increase in medical device sales, particularly in robotic surgery and patient support markets, demonstrating sustained demand in high-growth medical sectors.
- Future Outlook: Although Feldmann's direct shareholding decreased by 18%, she still holds 1,282 outstanding options, and CEO Jeffrey Bailly expressed optimism about the company's future, supported by a strong backlog and expanded manufacturing capacity, indicating robust long-term growth potential in the medical market.
See More
UFP Technologies Director Sells Shares
- Transaction Overview: On June 12, 2026, UFP Technologies director Cynthia L. Feldmann exercised options and immediately sold 1,200 shares for approximately $287,000 at around $239.29 per share, representing 18% of her direct stock holdings at the time.
- Shareholding Changes: Following this transaction, Feldmann's direct holdings decreased from 6,676 shares to 5,476 shares; however, she still retains 1,282 outstanding options, maintaining significant exposure to the company's future performance.
- Company Performance: UFP Technologies reported first-quarter revenue of $154.2 million, a 4.1% year-over-year increase, with net income rising to $17.5 million and adjusted earnings per share at $2.48, driven by a 5.9% increase in medical device sales, particularly in robotic surgery and patient support markets.
- Market Outlook Analysis: While Feldmann's stock transaction appears to be a liquidity event, it does not alter UFP Technologies' investment thesis, as CEO Jeffrey Bailly expressed optimism about the company's future due to strong backlog and expanding manufacturing capacity.
See More
UFP Technologies to Present at East Coast IDEAS Investor Conference
- Conference Details: UFP Technologies' CEO Mitchell Rock and CFO Ron Lataille will present at the East Coast IDEAS Investor Conference on June 10, 2026, at The Westin Times Square in New York, starting at 7:55 AM ET, highlighting the company's investment merits.
- Webcast Availability: The presentation will be webcasted through the conference host's main website, allowing investors to access it via UFP Technologies' investor relations page, thereby enhancing interaction and transparency with stakeholders.
- Conference Background: The IDEAS Investor Conferences aim to provide independent regional venues for quality companies, supported by sponsors managing over $200 billion in assets, underscoring UFP's market position in medical devices and custom products.
- Company Overview: UFP Technologies is a trusted contract development and manufacturing organization specializing in medical devices, sterile packaging, and highly engineered custom products, with applications across various medical fields including robotic-assisted surgery and infection control, showcasing its broad industry relevance.
See More
UFP Technologies Q1 2026 Earnings Call Insights
- Revenue Growth: UFP Technologies reported a 4.1% revenue increase in Q1 2026, with medical sales up 5.9% while non-medical sales declined by 15%, indicating a strategic focus on high-growth segments in the MedTech space amidst shifting market demands.
- New Program Developments: The company successfully launched four new programs, with three customers requesting to double their capacity, suggesting strong market demand and the potential for robust revenue growth in the second half of the year.
- Cost and Profitability Pressures: Although gross margin improved slightly to 28.8%, profitability was pressured by startup costs, AJR labor inefficiencies, and legal expenses related to a cyberattack, highlighting challenges faced during the expansion phase.
- Future Outlook: Management anticipates accelerated revenue growth in the second half of the year, particularly driven by new programs, while also planning to expand capacity in the APAC region to meet future market demands.
See More
UFP Technologies Q1 Earnings Beat Expectations
- Earnings Beat: UFP Technologies reported a Q1 non-GAAP EPS of $2.48, exceeding expectations by $0.17, indicating enhanced profitability that may attract more investor interest.
- Revenue Miss: The company's revenue of $154.2 million, while up 4.1% year-over-year, fell short of expectations by $0.58 million, reflecting challenges in market demand that could impact future growth outlook.
- Slight Operating Income Increase: Operating income rose 1.0% to $23.4 million in Q1, demonstrating the company's efforts in cost control and efficiency improvements, although the growth rate remains modest.
- Stable Adjusted Operating Income: Adjusted operating income for Q1 remained flat at $25.8 million compared to the same period last year, indicating stability in profitability but a lack of significant growth momentum.
See More
UFP Technologies Reports Q1 Adjusted EPS of $2.48, Exceeding IBES Estimate of $2.25
- Q1 Adjusted EPS: The adjusted earnings per share (EPS) for Q1 is reported at USD 2.48.
- IBES Estimate: This figure exceeds the IBES estimate, which was USD 2.25.
See More
Analysis of UFP Technologies Executive Stock Transaction
- Stock Option Exercise: UFP Technologies director Cynthia L. Feldmann exercised 1,200 stock options and immediately sold them on June 12 for a total value of $287,149, indicating a need for liquidity while maintaining 5,476 shares directly, which shows continued alignment with shareholders.
- Transaction Frequency Analysis: The 1,200-share sale is larger than the previous sale of 647 shares in November 2024 but smaller than a February sale, with most trading activity related to administrative events, indicating Feldmann's low trading frequency primarily aimed at realizing option liquidity.
- Company Financial Performance: UFP Technologies reported first-quarter revenue of $154.2 million, up 4.1% year-over-year, with net income at $17.5 million, reflecting a 5.9% increase in medical device sales, particularly in robotic surgery and patient support markets, demonstrating sustained demand in high-growth medical sectors.
- Future Outlook: Although Feldmann's direct shareholding decreased by 18%, she still holds 1,282 outstanding options, and CEO Jeffrey Bailly expressed optimism about the company's future, supported by a strong backlog and expanded manufacturing capacity, indicating robust long-term growth potential in the medical market.
See More
UFP Technologies Director Sells Shares
- Transaction Overview: On June 12, 2026, UFP Technologies director Cynthia L. Feldmann exercised options and immediately sold 1,200 shares for approximately $287,000 at around $239.29 per share, representing 18% of her direct stock holdings at the time.
- Shareholding Changes: Following this transaction, Feldmann's direct holdings decreased from 6,676 shares to 5,476 shares; however, she still retains 1,282 outstanding options, maintaining significant exposure to the company's future performance.
- Company Performance: UFP Technologies reported first-quarter revenue of $154.2 million, a 4.1% year-over-year increase, with net income rising to $17.5 million and adjusted earnings per share at $2.48, driven by a 5.9% increase in medical device sales, particularly in robotic surgery and patient support markets.
- Market Outlook Analysis: While Feldmann's stock transaction appears to be a liquidity event, it does not alter UFP Technologies' investment thesis, as CEO Jeffrey Bailly expressed optimism about the company's future due to strong backlog and expanding manufacturing capacity.
See More
UFP Technologies to Present at East Coast IDEAS Investor Conference
- Conference Details: UFP Technologies' CEO Mitchell Rock and CFO Ron Lataille will present at the East Coast IDEAS Investor Conference on June 10, 2026, at The Westin Times Square in New York, starting at 7:55 AM ET, highlighting the company's investment merits.
- Webcast Availability: The presentation will be webcasted through the conference host's main website, allowing investors to access it via UFP Technologies' investor relations page, thereby enhancing interaction and transparency with stakeholders.
- Conference Background: The IDEAS Investor Conferences aim to provide independent regional venues for quality companies, supported by sponsors managing over $200 billion in assets, underscoring UFP's market position in medical devices and custom products.
- Company Overview: UFP Technologies is a trusted contract development and manufacturing organization specializing in medical devices, sterile packaging, and highly engineered custom products, with applications across various medical fields including robotic-assisted surgery and infection control, showcasing its broad industry relevance.
See More
UFP Technologies Q1 2026 Earnings Call Insights
- Revenue Growth: UFP Technologies reported a 4.1% revenue increase in Q1 2026, with medical sales up 5.9% while non-medical sales declined by 15%, indicating a strategic focus on high-growth segments in the MedTech space amidst shifting market demands.
- New Program Developments: The company successfully launched four new programs, with three customers requesting to double their capacity, suggesting strong market demand and the potential for robust revenue growth in the second half of the year.
- Cost and Profitability Pressures: Although gross margin improved slightly to 28.8%, profitability was pressured by startup costs, AJR labor inefficiencies, and legal expenses related to a cyberattack, highlighting challenges faced during the expansion phase.
- Future Outlook: Management anticipates accelerated revenue growth in the second half of the year, particularly driven by new programs, while also planning to expand capacity in the APAC region to meet future market demands.
See More
UFP Technologies Q1 Earnings Beat Expectations
- Earnings Beat: UFP Technologies reported a Q1 non-GAAP EPS of $2.48, exceeding expectations by $0.17, indicating enhanced profitability that may attract more investor interest.
- Revenue Miss: The company's revenue of $154.2 million, while up 4.1% year-over-year, fell short of expectations by $0.58 million, reflecting challenges in market demand that could impact future growth outlook.
- Slight Operating Income Increase: Operating income rose 1.0% to $23.4 million in Q1, demonstrating the company's efforts in cost control and efficiency improvements, although the growth rate remains modest.
- Stable Adjusted Operating Income: Adjusted operating income for Q1 remained flat at $25.8 million compared to the same period last year, indicating stability in profitability but a lack of significant growth momentum.
See More
UFP Technologies Reports Q1 Adjusted EPS of $2.48, Exceeding IBES Estimate of $2.25
- Q1 Adjusted EPS: The adjusted earnings per share (EPS) for Q1 is reported at USD 2.48.
- IBES Estimate: This figure exceeds the IBES estimate, which was USD 2.25.
See More
